Sherlock Biosciences will develop molecular diagnostics tools co-developed by researchers at Harvard University and Broad Institute, including Crispr inventor Feng Zhang.
US-based biotechnology developer Sherlock Biosciences was launched out of Harvard University yesterday with a total of $35m in financing, including $17.5m in series A funding provided by the Open Philanthropy Project and unnamed investors.
The other $17.5m were supplied in the form of a non-dilutive grant by the Open Philanthropy Project, a non-profit group primarily funded by Dustin Moskovitz, a co-founder of social media firm Facebook, and his wife Cari Tuna.
The spinout is reportedly raising additional series A capital, though a target size could not be ascertained.
Sherlock Biosciences will exploit Crispr and synthetic biology to develop molecular diagnostics that are able to produce fast, accurate and inexpensive results for a wide array of needs in virtually any setting.
The spinout is named after one of its two platforms, Sherlock – an acronym for specific high-sensitivity enzymatic reporter unlocking – that identifies specific genetic targets…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
